Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study.

Ther Adv Med Oncol · 2026 · PMC13237275 · PMID 42254871

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

The exploratory subgroup analysis suggested a numerical trend favoring paclitaxel-ramucirumab among patients who experienced neuropathy during first-line treatment.

also in 723 other papers

did not reach statistical significanceno p-value reported

Exploratory subgroup analysis did not reach statistical significance.

also in 75,281 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.